K-V Gets FDA To Test Adequacy Of Makena’s Competing Compounded Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Compounded hydroxyprogesterone caproate and their APIs show they vary in potency and purity, K-V Pharmaceutical says; FDA is conducting its own analysis.